NASDAQ:IMMU - Immunomedics Stock Price, Price Target & More

$16.99 +0.77 (+4.75 %)

(As of 04/26/2018 11:06 AM ET)

Previous Close$16.22

Today's Range$16.29 - $17.30

52-Week Range$5.22 - $18.93

Volume883,679 shs

Average Volume2.13 million shs

Market Capitalization$2.67 billion

P/E Ratio-20.02

Dividend YieldN/A

Beta1.62

About Immunomedics (NASDAQ:IMMU)

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:IMMU

CUSIP45290710

Webwww.immunomedics.com

Phone973-605-8200

Debt

Debt-to-Equity Ratio1.20%

Current Ratio1.26%

Quick Ratio1.26%

Price-To-Earnings

Trailing P/E Ratio-20.02

Forward P/E Ratio-17.70

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.09 million

Price / Sales911.47

Cash FlowN/A

Price / CashN/A

Book Value($0.54) per share

Price / Book-31.46

Profitability

EPS (Most Recent Fiscal Year)($0.81)

Net Income$-153,200,000.00

Net Margins-7,187.83%

Return on EquityN/A

Return on Assets-76.04%

Miscellaneous

Employees138

Outstanding Shares165,770,000

How to Become a New Pot Stock Millionaire

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics (NASDAQ:IMMU) released its quarterly earnings results on Thursday, February, 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.09. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to analysts' expectations of $0.90 million. View Immunomedics' Earnings History.

What price target have analysts set for IMMU?

3 analysts have issued 1 year target prices for Immunomedics' shares. Their forecasts range from $15.00 to $27.00. On average, they anticipate Immunomedics' stock price to reach $21.00 in the next year. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 28,384,688 shares, an increase of 0.0% from the March 30th total of 28,374,585 shares. Based on an average daily volume of 1,764,283 shares, the short-interest ratio is currently 16.1 days. Currently, 20.3% of the shares of the stock are short sold.

Who are some of Immunomedics' key competitors?

Some companies that are related to Immunomedics include Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Intellia Therapeutics (NTLA), New England Nuclear (LNTH), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Nymox Pharmaceutical (NYMX), Quotient (QTNT), Trinity Biotech (TRIB), AspenBio Pharma (RIOT), Celldex Therapeutics (CLDX), Vermillion (VRML), Akers Biosciences (AKER) and ImmuCell (ICCC).

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

Dr. David M. Goldenberg, Former Founder (Age 80)
Mr. Michael R. Garone, CFO, Principal Accounting Officer & VP of Fin. (Age 59)
Mr. Michael F. Pehl, Pres, CEO & Director (Age 53)
Ms. Phyllis Parker, Director of Admin.
Dr. Chau Cheng, Sr. Director of Investor Relations & Corp. Sec.

Has Immunomedics been receiving favorable news coverage?

Media stories about IMMU stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Immunomedics earned a daily sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 47.48 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $16.99.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $2.67 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]

MarketBeat Community Rating for Immunomedics (IMMU)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		211 (Vote Outperform)
Underperform Votes:		176 (Vote Underperform)
Total Votes:		387

MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.

Immunomedics (NASDAQ:IMMU) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Immunomedics in the last 12 months. Their average twelve-month price target is $21.00, suggesting that the stock has a possible upside of 23.60%. The high price target for IMMU is $27.00 and the low price target for IMMU is $15.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$21.00	$21.00	$21.00	$15.50
Price Target Upside:	23.60% upside	15.96% upside	15.96% upside	32.93% upside

Immunomedics (NASDAQ:IMMU) Consensus Price Target History

Price Target History for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ:IMMU) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
1/24/2018	Jefferies Group	Boost Price Target	Buy	$22.00 -> $27.00	Medium
7/24/2017	Cowen	Reiterated Rating	Outperform	$15.00	Low
5/5/2017	Wells Fargo	Upgrade	Market Perform -> Outperform		High

(Data available from 4/26/2016 forward)

Immunomedics (NASDAQ:IMMU) Earnings History and Estimates Chart

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ:IMMU) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.11)	($0.11)	($0.11)
Q2 2018	1	($0.12)	($0.12)	($0.12)
Q3 2018	1	($0.14)	($0.14)	($0.14)
Q4 2018	1	($0.19)	($0.19)	($0.19)

Immunomedics (NASDAQ IMMU) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
2/8/2018	Q2 2018	($0.10)	($0.19)	$0.90 million	$0.60 million	View	N/A
11/9/2017	Q1 2018	($0.10)	($0.16)	$0.90 million	$0.69 million	View	N/A
8/16/2017	Q4 2017	($0.12)	($0.25)	$0.75 million	$0.64 million	View	N/A
5/10/2017	Q3 2017	($0.13)	($0.22)	$0.90 million	$1.32 million	View	N/A
2/9/2017	Q2 2017	($0.13)	($0.16)	$0.70 million	$0.38 million	View	Listen
11/2/2016	Q117	($0.14)	($0.17)	$0.70 million	$0.74 million	View	N/A
8/17/2016	Q416	($0.11)	($0.17)	$0.90 million	$0.93 million	View	Listen
5/4/2016	Q3	($0.13)	($0.15)	$0.70 million	$0.90 million	View	N/A
2/3/2016	Q216	($0.14)	($0.15)	$1.40 million	$0.67 million	View	N/A
11/4/2015	Q116	($0.14)	($0.16)	$1.23 million	$0.73 million	View	N/A
8/19/2015	Q415	($0.13)	($0.13)	$1.13 million	$2.40 million	View	Listen
5/6/2015	Q3 2015	($0.13)	($0.13)	$1.07 million	$1.18 million	View	N/A
2/4/2015	Q215	($0.13)	($0.12)	$1.73 million	$1.00 million	View	N/A
11/5/2014	Q1 2015	($0.12)	($0.13)	$1.18 million	$1.07 million	View	N/A
8/25/2014	Q414	($0.13)	($0.13)	$1.20 million	$1.20 million	View	N/A
5/7/2014	Q3 2014	($0.12)	$0.02	$1.13 million	$1.15 million	View	N/A
2/10/2014	Q214	($0.10)	($0.10)	$1.20 million	$1.20 million	View	N/A
11/4/2013	Q1 2014	($0.10)	($0.05)	$1.51 million	$5.50 million	View	N/A
8/22/2013	Q4 2013	($0.12)	($0.09)	$0.81 million	$1.40 million	View	N/A
5/8/2013	Q3 2013	($0.10)	$0.11	$0.97 million	$1.70 million	View	N/A
2/7/2013	Q2 2013	($0.09)	($0.07)			View	N/A
11/8/2012	Q1 2013	($0.08)	($0.10)			View	N/A
8/23/2012	Q4 2012	($0.08)	($0.10)			View	N/A
5/8/2012	Q3 2012	($0.08)	($0.10)			View	N/A
2/8/2012	Q2 2012	($0.08)	$0.27			View	N/A
11/4/2011	Q1 2012	($0.08)	($0.07)			View	N/A
8/24/2011	Q4 2011	($0.06)	$0.03			View	N/A
5/10/2011	Q3 2011	($0.06)	($0.10)			View	N/A
2/4/2011	Q2 2011	($0.08)	($0.05)			View	N/A
11/4/2010	Q1 2011	($0.07)	($0.09)			View	N/A
8/26/2010	Q4 2010	($0.08)	$0.01			View	N/A
5/10/2010	Q3 2010	($0.09)	$0.05			View	N/A
2/2/2010	Q2 2010	$0.03	$0.01			View	N/A
11/6/2009	Q1 2010	$0.43	$0.42			View	N/A
8/27/2009	Q4 2009	$0.01	$0.01			View	N/A
5/11/2009	Q3 2009	($0.01)	$0.01			View	N/A
2/9/2009	Q2 2009	($0.01)	$0.04			View	N/A
11/7/2008	Q1 2009		($0.03)			View	N/A
8/28/2008	Q4 2008	($0.08)	($0.09)			View	N/A
5/7/2008	Q3 2008		($0.08)			View	N/A
2/7/2008	Q2 2008	($0.09)	($0.04)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Immunomedics (NASDAQ:IMMU) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Immunomedics (NASDAQ IMMU) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.80%
Institutional Ownership Percentage: 74.49%

Insider Trading History for Immunomedics (NASDAQ:IMMU)

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ IMMU) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2018	David M Goldenberg	Director	Sell	20,000	$17.50	$350,000.00	1,774,285
3/5/2018	David M Goldenberg	Director	Sell	40,000	$17.24	$689,600.00	1,774,285
2/28/2018	David M Goldenberg	Director	Sell	17,729	$17.09	$302,988.61	1,774,285
11/20/2017	Brian A Markison	Director	Sell	8,390	$11.89	$99,757.10	99,178
11/15/2017	Behzad Aghazadeh	Insider	Buy	1,325,000	$10.47	$13,872,750.00
11/14/2017	Venbio Select Advisor Llc	Director	Buy	1,150,000	$10.39	$11,948,500.00
9/1/2017	David M. Goldenberg	Insider	Sell	20,000	$12.64	$252,800.00
8/28/2017	Cynthia L. Goldenberg	Director	Sell	40,000	$10.72	$428,800.00
8/23/2017	Cynthia L. Goldenberg	Director	Sell	40,000	$9.24	$369,600.00
8/24/2016	Don C Stark	Director	Sell	9,900	$2.97	$29,403.00	55,848
8/23/2016	Mary E Paetzold	Director	Sell	15,000	$2.98	$44,700.00	82,474
6/13/2016	Cynthia L Goldenberg	CEO	Sell	371,990	$3.03	$1,127,129.70	650,396
6/8/2016	Cynthia L Goldenberg	CEO	Sell	41,441	$3.62	$150,016.42	703,029
6/8/2016	David M Goldenberg	Chairman	Sell	353,010	$3.88	$1,369,678.80	2,602,063
6/7/2016	Cynthia L Goldenberg	CEO	Sell	4,600	$4.01	$18,446.00	703,029
6/7/2016	David M Goldenberg	Chairman	Sell	12,300	$3.98	$48,954.00	2,602,063
6/6/2016	Cynthia L Goldenberg	CEO	Sell	63,959	$4.09	$261,592.31	703,029
6/6/2016	David M Goldenberg	Chairman	Sell	110,322	$4.09	$451,216.98	2,602,063
6/15/2015	David M Goldenberg	Chairman	Sell	210,991	$4.08	$860,843.28
6/12/2015	Brian A Markison	Director	Sell	5,564	$4.22	$23,480.08
6/12/2015	David M Goldenberg	Chairman	Sell	359,653	$4.32	$1,553,700.96
6/9/2015	Mary E Paetzold	Director	Sell	4,677	$4.60	$21,514.20
6/5/2015	Don C Stark	Director	Sell	5,732	$4.14	$23,730.48
12/11/2014	Mary E Paetzold	Director	Sell	10,000	$4.71	$47,100.00
12/9/2014	Don C Stark	Director	Sell	5,500	$4.51	$24,805.00
9/13/2013	Don Stark	Director	Sell	10,000	$6.08	$60,800.00	22,000

(Data available from 1/1/2013 forward)

Immunomedics (NASDAQ IMMU) News Headlines

Source:

Date	Headline
	Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+ ... globenewswire.com - April 26 at 8:42 AM
	Immunomedics (IMMU) Announces Oral Presentation of Sacituzumab Govitecan in HR+ mBC at ASCO www.streetinsider.com - April 25 at 5:07 PM
	Myriad Genetics (MYGN) & Immunomedics (IMMU) Critical Review www.americanbankingnews.com - April 24 at 7:24 PM
	Reader Inquiry: Is There Further Upside In Immunomedics? seekingalpha.com - April 23 at 8:38 AM
	Immunomedics (IMMU) Upgraded at BidaskClub www.americanbankingnews.com - April 20 at 11:39 AM
	Immunomedics (IMMU) Rating Increased to Buy at Zacks Investment Research www.americanbankingnews.com - April 19 at 6:22 PM
	Immunomedics (IMMU) Rating Lowered to Hold at Zacks Investment Research www.americanbankingnews.com - April 18 at 10:48 PM
	Brokerages Anticipate Immunomedics (IMMU) Will Announce Earnings of -$0.13 Per Share www.americanbankingnews.com - April 17 at 7:08 PM
	When Will Immunomedics Inc (NASDAQ:IMMU) Become Profitable? finance.yahoo.com - April 17 at 5:26 PM
	BidaskClub Downgrades Immunomedics (IMMU) to Buy www.americanbankingnews.com - April 16 at 9:48 AM
	Today’s Research Reports on Trending Tickers: Exact Sciences and Immunomedics finance.yahoo.com - April 13 at 9:02 AM
	Immunomedics Target of Unusually Large Options Trading (IMMU) www.americanbankingnews.com - April 13 at 6:11 AM
	Immunomedics (IMMU) Upgraded at ValuEngine www.americanbankingnews.com - April 12 at 10:18 PM
	Immunomedics (IMMU) Short Interest Update www.americanbankingnews.com - April 12 at 2:17 AM
	Analyzing Intellia Therapeutics (NTLA) and Immunomedics (IMMU) www.americanbankingnews.com - April 11 at 1:24 AM
	Immunomedics (IMMU) Names Dr. Robert Iannone Head of Research & Development and CMO www.streetinsider.com - April 9 at 4:56 PM
	Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer finance.yahoo.com - April 9 at 9:00 AM
	Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Hold" by Analysts www.americanbankingnews.com - April 1 at 1:32 PM
	Brokerages Expect Immunomedics, Inc. (IMMU) Will Announce Earnings of -$0.13 Per Share www.americanbankingnews.com - March 31 at 7:14 PM
	Immunomedics (IMMU) Rating Lowered to Buy at BidaskClub www.americanbankingnews.com - March 26 at 9:55 AM
	Immunomedics (IMMU) Lifted to "Hold" at ValuEngine www.americanbankingnews.com - March 25 at 5:22 PM
	Immunomedics (IMMU) Cut to "Hold" at BidaskClub www.americanbankingnews.com - March 17 at 12:05 PM
	Analysts Expect Immunomedics, Inc. (IMMU) to Announce -$0.13 EPS www.americanbankingnews.com - March 14 at 5:24 PM
	David M. Goldenberg Sells 40,000 Shares of Immunomedics, Inc. (IMMU) Stock www.americanbankingnews.com - March 12 at 10:28 PM
	Immunomedics, Inc. (IMMU) Director David M. Goldenberg Sells 20,000 Shares www.americanbankingnews.com - March 12 at 10:26 PM
	Immunomedics, Inc. (IMMU) Director Sells $302,988.61 in Stock www.americanbankingnews.com - March 12 at 10:26 PM
	Immunomedics, Inc. (IMMU) Sees Significant Decline in Short Interest www.americanbankingnews.com - March 12 at 1:24 AM
	Immunomedics, Inc. (IMMU) Receives Average Rating of "Buy" from Analysts www.americanbankingnews.com - March 7 at 1:50 PM
	Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release) globenewswire.com - March 5 at 8:51 AM
	Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference finance.yahoo.com - March 5 at 8:51 AM
	Immunomedics, Inc. (IMMU) Stake Lessened by EAM Investors LLC www.americanbankingnews.com - March 2 at 1:32 PM
	Immunomedics (IMMU) Upgraded to Buy at BidaskClub www.americanbankingnews.com - February 25 at 5:28 PM
	-$0.13 EPS Expected for Immunomedics, Inc. (IMMU) This Quarter www.americanbankingnews.com - February 25 at 5:17 PM
	Immunomedics (IMMU) Upgraded by TheStreet to C- www.americanbankingnews.com - February 18 at 9:22 PM
	Zacks Investment Research Downgrades Immunomedics (IMMU) to Sell www.americanbankingnews.com - February 17 at 6:56 AM
	Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference finance.yahoo.com - February 15 at 8:20 AM
	Reviewing Immunomedics (IMMU) and Arsanis (ASNS) www.americanbankingnews.com - February 15 at 3:18 AM
	Blog Exposure - FDA Accepts Amicus Therapeutics’ NDA for Migalastat for Treatment of Fabry Disease finance.yahoo.com - February 14 at 9:33 AM
	Immunomedics (IMMU) Raised to "Buy" at BidaskClub www.americanbankingnews.com - February 11 at 8:10 AM
	Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Brokerages www.americanbankingnews.com - February 10 at 1:58 PM
	Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update finance.yahoo.com - February 9 at 9:35 AM
	Immunomedics reports 2Q loss finance.yahoo.com - February 9 at 9:35 AM
	Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018 finance.yahoo.com - February 6 at 9:31 AM
	Analyzing Ironwood Pharmaceuticals (IRWD) and Immunomedics (IMMU) www.americanbankingnews.com - January 31 at 5:12 PM
	Immunomedics (IMMU) Price Target Raised to $27.00 www.americanbankingnews.com - January 28 at 5:34 PM
	BidaskClub Upgrades Immunomedics (IMMU) to Strong-Buy www.americanbankingnews.com - January 28 at 8:54 AM
	Contrasting Celator Pharmaceuticals (CPXX) and Immunomedics (IMMU) www.americanbankingnews.com - January 28 at 7:18 AM
	Q3 2018 EPS Estimates for Immunomedics, Inc. Lifted by Analyst (IMMU) www.americanbankingnews.com - January 26 at 10:22 AM
	Interesting IMMU Put And Call Options For March 16th www.nasdaq.com - January 24 at 4:17 PM
	Immunomedics, Inc. (IMMU) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - January 16 at 2:08 PM

Immunomedics (NASDAQ:IMMU) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Immunomedics (NASDAQ:IMMU) Income Statement, Balance Sheet and Cash Flow Statement

Immunomedics (NASDAQ IMMU) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff